Truist raised the firm’s price target on OrthoPediatrics (KIDS) to $20 from $19 and keeps a Hold rating on the shares. The company’s Q4 EBITDA and free cash flow generation were “solid”, and with new product launches set to contribute in 2026, the firm continues to believe that the management’s 12% long range revenue outlook looks achievable, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KIDS:
- Buy Rating Backed by Strong Q4 Execution, FCF Inflection, and Undemanding Valuation Upside
- OrthoPediatrics price target raised to $22 from $20 at Stifel
- OrthoPediatrics price target raised to $24 from $23 at BTIG
- OrthoPediatrics Highlights Growth Strategy in 2026 Investor Presentation
- OrthoPediatrics announces iotaMotion received FDA 510k clearance for iotaSOFT